Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
18.60
Oct 22 • 12:58 PM ET Dollar change-0.03 Percentage change(-0.15%)
Index
-
Market Cap
3.60B
Enterprise Value
2.92B
Income
-91.90M
Sales
1.27B
Book/sh
6.35
Cash/sh
4.98
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
2900
IPO
Jun 05, 2020
P/E
-
Forward P/E
34.36
PEG
-
P/S
2.83
P/B
2.93
P/C
3.74
P/FCF
-
EV/EBITDA
-
EV/Sales
2.29
Quick Ratio
2.94
Current Ratio
3.04
Debt/Eq
0.23
LT Debt/Eq
0.09
Option/Short
Yes / Yes
EPS (ttm)
-0.51
EPS next Y
0.54
EPS next Q
-0.00
EPS this Y
94.69%
EPS next Y
1357.95%
EPS next 5Y
-
EPS past 3/5Y
16.80% 6.49%
Sales past 3/5Y
106.67% 68.87%
EPS Y/Y TTM
71.96%
Sales Y/Y TTM
59.59%
EPS Q/Q
125.11%
Sales Q/Q
51.64%
Insider Own
4.60%
Insider Trans
-0.43%
Inst Own
51.05%
Inst Trans
3.73%
ROA
-5.34%
ROE
-8.11%
ROIC
-6.86%
Gross Margin
53.00%
Oper. Margin
-4.12%
Profit Margin
-7.21%
SMA20
-1.10%
SMA50
-4.78%
SMA200
-16.16%
Trades
Shs Outstand
193.77M
Shs Float
184.85M
52W High
37.50 -50.40%
52W Low
16.24 14.54%
Volatility
4.91% 4.78%
ATR (14)
0.89
RSI (14)
47.15
Beta
0.57
Rel Volume
0.43
Avg Volume
2.30M
Volume
557,521
Perf Week
-6.05%
Perf Month
0.82%
Perf Quarter
-16.28%
Perf Half Y
-22.46%
Perf YTD
-14.44%
Perf Year
-42.07%
Perf 3Y
-72.04%
Perf 5Y
-64.96%
Perf 10Y
-
Prev Close
18.63
Price
18.60
Change %
-0.15%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanders Corazon (Corsee) D.DirectorSep 29 '26Sale9.4627,370258,92052,731Oct 01 04:04 PM
Sanders Corazon (Corsee) D.DirectorSep 29 '26Proposed Sale18.9213,685258,915Sep 29 02:31 PM
Santos Carlos EChief Financial OfficerSep 21 '26Sale9.145,43049,63014,246Sep 23 04:15 PM
Santos Carlos EOfficerSep 22 '26Proposed Sale18.732,71550,854Sep 22 03:30 PM
Huang YingFormer Officer & DirectorSep 22 '26Proposed Sale18.6569,8121,302,109Sep 22 02:33 PM
Casey Patrick JohnDirectorJun 30 '26Proposed Sale29.603,00088,800Jun 30 10:46 AM
Huang YingChief Executive OfficerJun 25 '26Sale14.785,56682,265241,872Jun 29 09:53 PM
Huang YingOfficerJun 26 '26Proposed Sale28.392,78379,017Jun 26 03:23 PM
Huang YingChief Executive OfficerMar 25 '26Sale8.779,93687,139247,438Mar 27 04:25 PM
Huang YingOfficerMar 26 '26Proposed Sale17.544,96887,149Mar 26 04:27 PM
Yeung JessieOfficerMar 26 '26Proposed Sale17.541,86232,663Mar 26 04:20 PM
Huang YingOfficerDec 26 '25Proposed Sale22.5264,3391,449,074Dec 29 07:28 AM
Sanders Corazon (Corsee) D.DirectorDec 24 '25Proposed Sale22.7796922,064Dec 29 06:45 AM
Huang YingOfficerDec 24 '25Proposed Sale22.9561,4671,410,606Dec 29 06:40 AM
GenScript CorporationAffiliateNov 17 '25Proposed Sale30.29203,5866,166,620Nov 17 05:50 PM
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Bridgewater, NJ.
Chief Executive OfficerMs. Ingrid Zhang
Chief Financial OfficerMr. Carlos Santos Garcia
J.D.Ms. Ananda Elizabeth Martin Esq.
General CounselMr. Robert Staloff
Interim Head of Research & Development and Senior VP of Regulatory AffairsDr. Yuhong Qiu Ph.D.